11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 11.06.2026 Expectation: 1650 pips
Selling S&P 500 with 7,370 in sight on rising likelihood of Fed’s hawkish policy
Today at 11:51 AM 15
Gold buy
Period: 05.06.2026 Expectation: 290 pips
Buying gold with $4,770 in view
Today at 11:13 AM 25
Period: 31.10.2026 Expectation: 1000 pips
Buying Ethereum up to $2,800
Today at 10:59 AM 10
Period: 15.06.2026 Expectation: 600 pips
Invest in SPX as job growth holds steady
Today at 10:59 AM 6
Period: 04.07.2026 Expectation: 2150 pips
Invest in USDJPY up to 162.00
Today at 10:25 AM 10
Period: 11.06.2026 Expectation: 27000 pips
Buying ETHUSD with $2,050 target if geopolitical climate improves and risk appetite rises
Today at 08:24 AM 16
Go to forecasts